Acupuncture needles join fight against lung cancer

NCT ID NCT07239661

Recruiting now Disease control Sponsor: Kong Fanming Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding electroacupuncture (a type of acupuncture with mild electric current) to standard immunotherapy can help control advanced non-small cell lung cancer in patients who are too weak for aggressive treatment. 120 participants will receive either real or sham electroacupuncture alongside their PD-1 inhibitor drugs. The goal is to see if the combination delays cancer progression and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: electroacupuncture
What this could lead to: If it works, this could show that adding electroacupuncture to immunotherapy helps control advanced lung cancer and improves quality of life for patients with limited mobility.
What could go wrong: This is an early-stage trial with no phase designation, so results are uncertain. The sham control group may also show benefits, making it hard to prove electroacupuncture's specific effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ECOG PS 2 POINTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ECOG PS 2 POINTS ELECTROACUPUNCTURE NON-SMALL CELL LUNG CANCER PD-1 INHIBITORS

Contacts and locations

Locations

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
RECRUITING

Tianjin, Tianjin Municipality, 300193, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.